Lexeo links gene therapy to improvements in rare heart disease
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN...
Clinical-stage genetic medicine company Lexeo Therapeutics has won fast track designation from the US Food and Drug Administration (FDA) for its gene therapy candidate LX2006, designed to treat Friedreich's ataxia (FA) cardiomyopathy
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006
Lexeo Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results